In this issue of Blood, Quintanilla-Martinez and colleagues describe a series of Hydroa vacciniforme–like lymphoma (HVLL) and find that this is an Epstein-Barr virus (EBV)-associated lymphoproliferative disorder with a diverse (αβ−, γδ−, or NK−) phenotype and a broad clinical spectrum, in most cases showing a prolonged clinical course, but with a distinct risk for progression to systemic disease.1

HVLL is a chronic lymphoproliferative disorder that may in the initial phase respond favorably to conservative therapy using immunomodulators and/or immunosuppressive agents. Although this is not a clinical trial, the results are consistent with other reported observations. This allows them to recommend less aggressive therapy for the initial stages of the disease.

HVLL is a fascinating disorder that teaches us about a specific model of development of a systemic lymphoproliferative disorder. Thus, the data are consistent with the interpretation that, after an initial EBV exposure, patients with a particular genetic background develop a disorder characterized by the presence of persistent T-cell clones with a cytotoxic or NK phenotype. In response to different inflammatory stimuli, such as mosquito bites or sunburns, the patients develop local inflammatory sites that recruit the monoclonal T cells. This may evolve as a self-limited disorder that may recur after additional local insults. Additional genetic or environmental events may eventually trigger a more aggressive disorder in a fraction of these patients (see figure).

These observations give additional support to the thesis that inflammatory sites may play a role in the pathogenesis of the early steps of different lymphoproliferative disorders. Circulating monoclonal T or B cells may then populate these inflammatory sites, but this finding does not necessarily reflect tumoral progression.

Consistently with observations and reflections performed in other areas of pathology, the authors propose not to label these lesions as lymphoma, restricting the use of this term to the aggressive steps of the disorder requiring cytotoxic therapy.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES


Cutaneous EBV-associated lymphoma?

Miguel A. Piris and Carlos Barrionuevo Cornejo